Navigation Links
DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME
Date:10/17/2007

as found no significant issues in the treatment of patients with Medidur over the past 18 months in the recruitment phase of this pivotal study," said pSivida Limited Managing Director, Dr. Paul Ashton.

Currently, 7.5 percent of the US population is diabetic. Over time, almost all diabetics will develop some form of diabetic retinopathy, of which diabetic macular edema is the primary cause of vision loss. There are currently more than 500,000 people with DME in the United States and this number is expected to exceed 700,000 by the year 2010; approximately 75,000 new cases of DME are diagnosed each year.

About Alimera Sciences Inc.

Alimera Sciences Inc., an Atlanta, GA. venture backed company, specializes in the development and commercialization of prescription ophthalmology pharmaceuticals. Founded by an executive team with extensive development and revenue growth expertise, Alimera Sciences' products are focused on improving the delivery of therapeutic agents to enhance patients' lives and strengthen physicians' ability to manage ocular conditions. Alimera is currently conducting a Phase 3 clinical trial of fluocinolone acetonide in the Medidur(TM) drug delivery system for the treatment of diabetic macular edema. For more information, please visit http://www.alimerasciences.com

About pSivida Limited

pSivida, a Boston, MA. based global drug delivery company, is committed to the biomedical sector. Retisert(R) is FDA approved for the treatment of uveitis. Vitrasert(R) is FDA approved for the treatment of AIDS-related CMV Retinitis. Bausch & Lomb own the trademarks Vitrasert(R) and Retisert(R). pSivida has licensed the technologies underlying both of these products to Bausch & Lomb. The technology underlying Medidur(TM) for diabetic macular edema is licensed to Alimera Sciences and is in Phase 3 clinical trials. pSivida has a worldwide collaborative research and license agreement w
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Vitamin E supports Female Hearts
2. Injection supports Heart Devices
3. Study supports vegetable diet
4. Study supports century-old cancer theory
5. Google Supports Indians Novel Literacy Drive
6. Actor Anil Kapoor Supports Birth Registration Cause
7. AMA Supports Tax Penalty for Uninsured Americans
8. Church Supports HIV Test Before Marriage
9. EHRVA Supports EHR Product Certification
10. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
11. Bush Supports Restriction to ‘Morning–After’ Pll
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 Now offering innovative, safe, and ... of Dr. Hedi Belajouza in Tunisia extends ... Perfection to the last detail — meticulous hair placement, ... of the harvested follicle — are all results in ... visible in the artistry and talent of Tunisian hair ...
(Date:5/26/2015)... 26, 2015 The American Association of ... 55 poison centers applaud the efforts of the United ... according to Stephen T. Kaminski, JD, AAPCC CEO and ... Substances Act, introduced by Senator Edward J. Markey on ... opioid pain medications and other controlled substances to undergo ...
(Date:5/26/2015)... (PRWEB) May 26, 2015 Sexual harassment and ... Title IX is best known for creating opportunities in women's ... for sexual assault response and prevention. In a recent episode ... Global Sports Advocates explains what Title IX means for ... get in front of this issue to protect students. , ...
(Date:5/26/2015)... 2015 Marching bands across the ... and thanks to the efforts of Etymotic Research, ... their musicians are protecting their hearing with Etymotic’s ... participating groups, Etymotic’s Adopt-a-Band program continues to add ... now for sale in drum shops and musical ...
(Date:5/26/2015)... 26, 2015 Irwin Gross, M.D., ... a hospital-wide Patient Blood Management (PBM) initiative at Eastern ... blood usage by more than 60 percent and improved ... in detail in an article in the May 2015 ... reduced perioperative red cell loss, less acute kidney injury ...
Breaking Medicine News(10 mins):Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 2Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 3Health News:Hair Transplant Center in Tunisia Now Offering Innovative Restoration Technology 4Health News:American Association of Poison Control Centers Supports Legislative Initiatives Targeting the Responsible Prescription of Opioid Pain Medication 2Health News:American Association of Poison Control Centers Supports Legislative Initiatives Targeting the Responsible Prescription of Opioid Pain Medication 3Health News:Paul Greene Explores Title IX and College Sports on SCI TV 2Health News:Paul Greene Explores Title IX and College Sports on SCI TV 3Health News:Marching Musicians Getting In Step With Hearing Protection 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 2Health News:Published Study: Patient Blood Management (PBM) Program Slashes Blood Use, Transfusions and Costs while Resulting in Better Patient Outcomes 3
... development of a healthy "designer fat" that, when added to ... in high quantities, but isn,t available in large enough amounts ... oil, also could boost nutrition for babies who are bottle-fed ... of Agricultural and Food Chemistry . Casimir Akoh and ...
... comprehensive analyses to date of the cost of robotic-assisted, laparoscopic ... now-dominant surgical approach is significantly more costly than standard open ... The results of the study are available online and will ... . In one of the first studies based ...
... WASHINGTON - The second edition of Law and the American ... 15, 2012. Building on its 1997 predecessor, the second edition ... of law and the U.S. health care system. Law and ... unprecedented change in how health care is organized, financed, and ...
... new study at Karlstad University in Sweden shows that phthalates ... Phthalates are substances suspected to cause asthma and allergies, as ... that children can ingest these softening agents with food but ... a group of chemical compounds that occur in construction materials ...
... HealthDay Reporter , TUESDAY, May 22 (HealthDay News) ... procedure, which involves threading a camera through the colon ... new study has found that patients overwhelmingly preferred colonoscopy ... scan. Colonoscopy has long been the standard ...
... Prior treatment with inhaled corticosteroids in patients with ... associated with a lower incidence and severity of parapneumonic ... Spain. , A parapneumonic effusion is a type of ... pleural layers, the fluid-filled space that surrounds the lungs) ...
Cached Medicine News:Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 2Health News:Robotic-assisted prostate cancer surgery drives up costs, UPMC study finds 3Health News:Landmark textbook on health care and the US legal system released 2Health News:Phthalates in PVC floors taken up by the body in infants 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 2Health News:Patients Prefer More Invasive Form of Colon Scan: Study 3Health News:Long-term ICS use reduces pleural effusion in patients with CAP 2
(Date:5/26/2015)... , May 26, 2015  AbbVie (NYSE: ... Phase 3 GIFT-I study of its investigational, all-oral, ... treatment with ombitasvir/paritaprevir/ritonavir at the Annual Meeting of ... Japan . 1 GIFT-I evaluated ... infected Japanese patients, with and without cirrhosis, who ...
(Date:5/26/2015)... -- Thoratec Corporation (NASDAQ: THOR ), a world ... and restore failing hearts, said today it will participate ... Conference on Tuesday, June 9. D. ... provide an update on the company, beginning at 2:00 ... The presentation will be available through the ...
(Date:5/26/2015)... , May 26, 2015  Amgen (NASDAQ: AMGN ... the Phase 3 OPTiM study in the Journal ... The data published in JCO , which were ... Society of Clinical Oncology (ASCO) in 2013 and 2014, ... patients with unresected stage IIIB, IIIC or IV metastatic ...
Breaking Medicine Technology:AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 2AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 3AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 4AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 5AbbVie Presents New Data for its Investigational Hepatitis C Treatment in Japanese Patients With and Without Cirrhosis 6Thoratec Presentation At Goldman Sachs Healthcare Conference To Be Webcast 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 2Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 3Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 4Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 5Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 6Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 7Pivotal Study Results Published in Journal of Clinical Oncology Showed Talimogene Laherparepvec Improved Durable Response Rates in Patients With Metastatic Melanoma 8
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
Trident Hemispherical Acetabular Shells are a true hemispherical shape designed to achieve press-fit fixation by under-reaming the acetabulum....
For primary and revision cases...
The MPF cup is specifically designed to achieve high primary stability, a critical factor for long term success....
Medicine Products: